Therapeutic potential of midkine in cardiovascular disease

Kenji Kadomatsu, Péter Bencsik, A. Görbe, C. Csonka, Kazuma Sakamoto, Satoshi Kishida, P. Ferdinándy

Research output: Article

16 Citations (Scopus)

Abstract

Ischaemic heart disease, stroke and their pathological consequences are life-threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti-Apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti-Apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.

Original languageEnglish
Pages (from-to)936-944
Number of pages9
JournalBritish Journal of Pharmacology
Volume171
Issue number4
DOIs
Publication statusPublished - febr. 2014

Fingerprint

Cardiovascular Diseases
Blood Vessels
Pathologic Constriction
Therapeutics
Reperfusion Injury
Neointima
midkine
Developed Countries
Myocardial Ischemia
Neoplasms
Intercellular Signaling Peptides and Proteins
Cell Death
Endothelial Cells
Stroke
Cell Proliferation
Pathology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic potential of midkine in cardiovascular disease. / Kadomatsu, Kenji; Bencsik, Péter; Görbe, A.; Csonka, C.; Sakamoto, Kazuma; Kishida, Satoshi; Ferdinándy, P.

In: British Journal of Pharmacology, Vol. 171, No. 4, 02.2014, p. 936-944.

Research output: Article

Kadomatsu, Kenji ; Bencsik, Péter ; Görbe, A. ; Csonka, C. ; Sakamoto, Kazuma ; Kishida, Satoshi ; Ferdinándy, P. / Therapeutic potential of midkine in cardiovascular disease. In: British Journal of Pharmacology. 2014 ; Vol. 171, No. 4. pp. 936-944.
@article{d17683edbb41442c95cedbe21c28c405,
title = "Therapeutic potential of midkine in cardiovascular disease",
abstract = "Ischaemic heart disease, stroke and their pathological consequences are life-threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti-Apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti-Apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.",
keywords = "angiogenesis, apoptosis, brain, cardioprotection, heart, infarction, inflammation, ischaemia/reperfusion, remodeling, vascular stenosis",
author = "Kenji Kadomatsu and P{\'e}ter Bencsik and A. G{\"o}rbe and C. Csonka and Kazuma Sakamoto and Satoshi Kishida and P. Ferdin{\'a}ndy",
year = "2014",
month = "2",
doi = "10.1111/bph.12537",
language = "English",
volume = "171",
pages = "936--944",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Therapeutic potential of midkine in cardiovascular disease

AU - Kadomatsu, Kenji

AU - Bencsik, Péter

AU - Görbe, A.

AU - Csonka, C.

AU - Sakamoto, Kazuma

AU - Kishida, Satoshi

AU - Ferdinándy, P.

PY - 2014/2

Y1 - 2014/2

N2 - Ischaemic heart disease, stroke and their pathological consequences are life-threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti-Apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti-Apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.

AB - Ischaemic heart disease, stroke and their pathological consequences are life-threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti-Apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti-Apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.

KW - angiogenesis

KW - apoptosis

KW - brain

KW - cardioprotection

KW - heart

KW - infarction

KW - inflammation

KW - ischaemia/reperfusion

KW - remodeling

KW - vascular stenosis

UR - http://www.scopus.com/inward/record.url?scp=84893029600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893029600&partnerID=8YFLogxK

U2 - 10.1111/bph.12537

DO - 10.1111/bph.12537

M3 - Article

C2 - 24286213

AN - SCOPUS:84893029600

VL - 171

SP - 936

EP - 944

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -